SCHEMBL13326565

SCHEMBL13326565

CN1c2ccc(-c3ccccc3)cc2Cc2cc(-c3ccccc3)ccc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 2/20 0.43
CYP11B2 P19099 2/20 0.43
CYP17A1 P05093 1/20 0.43
CYP1A2 P05177 1/20 0.43
CYP19A1 P11511 1/20 0.43
SRD5A1 P18405 1/20 0.42
TDP2 O95551 1/20 0.41
HSD17B3 P37058 2/20 0.41
BMPR1B O00238 3/20 0.40
BMPR1A P36894 3/20 0.40
ACVRL1 P37023 3/20 0.40
ACVR1 Q04771 3/20 0.40
TRIM24 O15164 1/20 0.40
HRH3 Q9Y5N1 1/20 0.38
TGFBR1 P36897 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
TSHR P16473 1/20 0.38
DRD2 P14416 1/20 0.38
POLB P06746 1/20 0.38
NPC1 O15118 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13326613 0.92 PDE5A (0.43) CYP11B1CYP11B2CYP17A1CYP1A2CYP19A1
SCHEMBL5068071 0.81 ALDH1A1 (0.43) CYP1A2ACVR1SMN1; SMN2NPC1MAPT
SCHEMBL5069422 0.79 MAOA (0.41) HSD17B3ACVR1MAPT
SCHEMBL13827544 0.79 FAAH (0.44) CYP11B1CYP11B2SRD5A1TDP2HSD17B3
SCHEMBL13326569 0.78 ACVRL1 (0.36) CYP11B1CYP11B2CYP17A1CYP1A2CYP19A1
SCHEMBL769234 0.77 ACVRL1 (0.71) CYP11B1CYP11B2CYP17A1CYP1A2CYP19A1
SCHEMBL20905279 0.77 CYP11B1 (0.50) CYP11B1CYP11B2CYP17A1CYP1A2CYP19A1
SCHEMBL2493673 0.77 MAOA (0.55) DRD2MAPTMAPK1
SCHEMBL16502139 0.76 APP (0.41) CYP11B1CYP11B2SRD5A1TDP2HSD17B3
SCHEMBL18596812 0.76 HSD17B3 (0.36) CYP11B1CYP11B2CYP17A1CYP1A2CYP19A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7718278-B2 Anthrancene derivative compound and organic light-emitting device including the same SAMSUNG ELECTRONICS CO., LTD. (KR) 2010-05-18 US disclosed
US-20080122346-A1 ANTHRANCENE DERIVATIVE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME SAMSUNG ELECTRONICS CO., LTD. (KR) 2008-05-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080122346-A1 ANTHRANCENE DERIVATIVE COMPOUND AND ORGANIC LIGHT-EMITTING DEVICE INCLUDING THE SAME AR, CRY2, ANTXR2 CYP11B1 424/4885CYP11B2 404/4885CYP17A1 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.